Serological test and chest computed tomography findings in patients with<i>Mycobacterium avium</i>complex lung disease

Kitada, Shuichi; Nishiuchi, Yukiko; Hiraga, Toru; Naka, Nobuyuki; Hashimoto, Hisako; Yoshimura, K.; Miki, Keisuke; Miki, Mari; Motone, Masaharu; Fujikawa, Takuya; Kobayashi, Keiko; Yano, Ikuya; Maekura, Ryoji

doi:10.1183/09031936.00061806

Cited by 27 publications

(22 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A weak positive correlation between the extent of MAC-PD on chest CT and antibody levels was observed (r50.24, p50.0309), as reported in previous studies [9,10]. This observation may indicate that the antibody levels reflect MAC disease activity.…”

Section: Discussionsupporting

confidence: 66%

“…To assess the extent of disease, we divided the lung into 18 segments on a conventional chest CT, according to the anatomical segments, as in previous studies [9,10]. The extent of disease was expressed as the number of involved CT segments in which MAC lesions were present.…”

Section: Chest Computed Tomographymentioning

confidence: 99%

“…Previous Japanese studies reported the usefulness of a serodiagnostic test for MAC-PD [7][8][9][10]. The test is an enzyme immunoassay (EIA) that detects serum immunoglobulin (Ig)A antibodies directed against the glycopeptidolipid (GPL) core, a component of the mycobacterial cell wall [11,12].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Serodiagnosis ofMycobacterium aviumcomplex pulmonary disease in the USA

et al. 2012

View full text Add to dashboard Cite

Diagnosis of Mycobacterium avium complex pulmonary disease (MAC-PD) can be difficult. A previous study from Japan reported the usefulness of a serodiagnostic test for MAC-PD. The objective of this study was to evaluate the usefulness of the test in similar patients in the USA. 100 patients with known or suspected MAC-PD and 52 healthy volunteers were enrolled into the study at National Jewish Health, Denver, CO, USA. Serum glycopeptidolipid core immunoglobulin A antibody levels were measured with an enzyme immunoassay (EIA) kit and routine clinical evaluations were performed.The patients were divided into two groups based on clinical evaluation: 87 patients with MAC-PD that met American Thoracic Society criteria, and 13 who did not meet the criteria. The sensitivity and specificity (cut-off point 0.3 U?mL -1 ) of the serodiagnostic test for diagnosing MAC-PD were 70.1% and 93.9%, respectively. Among the 44 patients in the MAC-PD group with two or more positive sputum cultures within the previous 6 months, sensitivity was 81.8%.The EIA kit demonstrated good sensitivity and specificity for the identification of MAC-PD, particularly in patients with two or more positive cultures, and may be useful for rapid MAC-PD diagnosis. @ERSpublications Serodiagnostic test for Mycobacterium avium complex pulmonary disease demonstrated good sensitivity and specificity

show abstract

Section: Discussionsupporting

confidence: 66%

Section: Chest Computed Tomographymentioning

confidence: 99%

See 1 more Smart Citation

Serodiagnosis ofMycobacterium aviumcomplex pulmonary disease in the USA

et al. 2012

View full text Add to dashboard Cite

show abstract

“…The disease type was determined on the basis of the HRCT results as previously described (6). The extent of the disease was defined based on the number of CT segments in which MAC lesions were present, as described previously (6,22).…”

Section: Methodsmentioning

confidence: 99%

“…Other studies found a weak correlation between the GPL core antibody levels and the extent of the disease on chest computed tomography (CT) (9,22). In addition, the antibody levels were found to be decreased after surgical resection in patients with MAC pulmonary disease (21).…”

mentioning

confidence: 98%

Levels of Antibody against Glycopeptidolipid Core as a Marker for Monitoring Treatment Response in Mycobacterium avium Complex Pulmonary Disease: a Prospective Cohort Study

et al. 2017

View full text Add to dashboard Cite

The diagnosis of Mycobacterium avium complex pulmonary disease (MAC-PD) is sometimes complicated and time-consuming. A serodiagnostic kit that measures the serum levels of IgA antibodies against the glycopeptidolipid (GPL) core is commercially available and has good diagnostic accuracy for MAC-PD. However, the significance of measurement of GPL core IgA antibody levels in monitoring for chemotherapy response in patients with MAC-PD was not well investigated. Thirty-four treatment naive MAC-PD patients who were started on multidrug chemotherapy were enrolled. Their antibody levels were prospectively measured at regular intervals. The relationships between their antibody levels and the therapeutic outcomes were examined. The patients were classified into three groups (conversion, recurrence, and nonconversion) based on the bacteriological outcomes after chemotherapy. There were no significant differences in the antibody levels before treatment between the culture conversion (n ϭ 19), recurrence (n ϭ 7), and nonconversion (n ϭ 8) groups (P ϭ 0.9881). The levels decreased significantly after the chemotherapy (P Ͻ 0.0001). Recurrence and/or worsening of chest radiography findings were observed in cases whose antibody levels subsequently increased after cessation of the chemotherapy. No significant difference in the percent decrease in antibody levels by the chemotherapy was observed between the culture conversion and recurrence groups (P ϭ 0.9338). The initial antibody levels are not a predictor of therapeutic outcomes, and also the percent decrease in antibody levels is not a sufficient indicator of the cessation of chemotherapy. However, serial measurements of antibody levels may allow objective monitoring of disease activity in individual MAC-PD patients.

show abstract

Glycopeptidolipids: Immuno‐modulators in greasy mycobacterial cell envelope

Mukherjee¹,

Chatterji²

2012

IUBMB Life

View full text Add to dashboard Cite

SummarySpecies of opportunistic mycobacteria are the major causative agent for disseminating pulmonary infections in immunocompromised individuals. These naturally resistant strains recruit a unique type of glycolipid known as glycopeptidolipids (GPLs), noncovalently attached to the outer surface of their thick lipid rich cell envelope. Species specific GPLs constitute the chemical determinants of most nontuberculous mycobacterial serotypes, and their absence from the cell surface confers altered colony morphology, hydrophobicity, and inability to grow as biofilms. The objective of this review is to present a comprehensive account and highlight the renewed interest on this much neglected group of pleiotropic molecules with respect to their structural diversity and biosynthesis. In addition, the role of GPLs in mycobacterial survival, both intracellular and in the environment is also discussed. It also explores the possibility of identifying new targets for intervening Mycobacterium avium complex-related infections. These antigenic molecules have been considered to play a pivotal role in immune suppression and can also induce various cytokine mediated innate immune responses, the molecular mechanism of which remains obscure. IUBMBIUBMB Life, 64(3): 215-225, 2012

show abstract

Serological test and chest computed tomography findings in patients withMycobacterium aviumcomplex lung disease

Cited by 27 publications

References 19 publications

Serodiagnosis ofMycobacterium aviumcomplex pulmonary disease in the USA

Serodiagnosis ofMycobacterium aviumcomplex pulmonary disease in the USA

Levels of Antibody against Glycopeptidolipid Core as a Marker for Monitoring Treatment Response in Mycobacterium avium Complex Pulmonary Disease: a Prospective Cohort Study

Glycopeptidolipids: Immuno‐modulators in greasy mycobacterial cell envelope

Contact Info

Product

Resources

About